Hey, Brand new study just came out in the lancet.

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30566-X/fulltext

• double-blind, placebo-controlled trial
• Between May 18, and Sept 4, 2020, we recruited 30 patients per group. The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon lambda than placebo from day 3 onwards, with a difference of 2·42 log copies per mL at day 7 (p=0·0041). By day 7, 24 (80%) participants in the peginterferon lambda group had an undetectable viral load, compared with 19 (63%) in the placebo group (p=0·15).
• Peginterferon lambda accelerated viral decline in outpatients with COVID-19, increasing the proportion of patients with viral clearance by day 7, particularly in those with high baseline viral load. Peginterferon lambda has potential to prevent clinical deterioration and shorten duration of viral shedding.
• Study limitations include the small sample size
• The benefit of treatment was more pronounced in the group with high baseline viral load than in those with low baseline viral load.
• Peginterferon lambda was well tolerated with no identified safety concerns. Side-effects of peginterferon lambda overlap with COVID-19 symptoms, making distinguishing whether adverse events were related to treatment or the infection difficult. As has been reported previously,3 symptoms were more prominent in those with higher viral loads. With detailed serial symptom assessment, we found that symptoms improved in both groups over time. Notably, among those who were asymptomatic at baseline, we found no difference in the number of adverse events between the treatment and placebo groups.
• Having shown safety and efficacy in an ambulatory cohort, we and others are now investigating the clinical benefit of peginterferon lambda in patients admitted to hospital with COVID-19.
• In conclusion, peginterferon lambda is among the first antiviral therapies to show benefit among outpatients with COVID-19. Peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral load. This treatment might have potential to avert clinical deterioration, shorten the duration of infectiousness, and reduce isolation time, with substantial public health and societal effects.

Hope this helps as well.

I couldn't find much that had serious evidence behind it when I was trying to help others, so I understand.

I was lucky to find this information, so I'm happy to pass it along.